For example, nonclinical testing of semorinemab was in a mouse model expressing P301L tau, a mutation found in FTLD (usually a behavioral variant FTD phenotype), with subsequent clinical testing in AD patients (84). Here, MAPT is linked to frontotemporal dementia.